Variance in contribution level seen by condition and subpopulation
WEDNESDAY, Sept. 11, 2024 (HealthDay News) — The population-attributable fraction of dementia from vision impairments ranges from 4.9 to 19.0 percent, according to a study published online Sept. 5 in JAMA Ophthalmology.
Jason R. Smith, from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues estimated the contribution of vision impairments to dementia using data from the National Health and Aging Trends Study (2,767 community-dwelling Medicare beneficiaries aged 65 years and older).
The researchers found that the population-attributable fraction of prevalent dementia from at least one vision impairment was 19.0 percent. The strongest attributable fraction among all impairments was seen for contrast sensitivity impairment (15.0 percent), followed by near acuity (9.7 percent) and distance acuity (4.9 percent). Population-level dementia-attributable fractions from at least one visual impairment were highest among subpopulations of participants aged 71 to 79 years (24.3 percent), female individuals (26.8 percent), and non-Hispanic White individuals (22.3 percent), with estimates consistent across educational strata.
“While not proving a cause-and-effect relationship, these findings support inclusion of multiple objective measures of vision impairments, including contrast sensitivity and visual acuity, to capture the total potential impact of addressing vision impairment on dementia,” the authors write.
Several authors disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Virtual Reality-Based Digital Defocus Vision Training May Aid Myopia in Children
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Highly Aspherical Lenslets Effective for Reducing Myopia Progression in Children
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers